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Objectives: To critically analyse radiotherapy cost studies published over the last 
35 years. MethOds: We conducted a comprehensive and systematic review of the 
literature searching for radiotherapy cost calculation studies on PubMed (Medline) 
and Embase databases and in the grey literature. The searches yielded 1327 unique 
entries that were evaluated against the following selection criteria: actual medical 
cost, external beam radiotherapy (EBRT), clear description of the cost calcula-
tion method. The review for compliance with the criteria was conducted in three 
phases: title; abstract and then full manuscript. Results: Since 1981, 50 studies 
satisfied our selection criteria. Any perspective, e.g. societal, institutional, was 
considered acceptable as long as the institutional resources ‘cost of radiotherapy 
was presented. Cost assessments of EBRT were conducted within a full economic 
evaluation framework (5 studies: 2 CEA, 2 CUA, and 1 CBA), cost analysis (24), cost 
description (18) and investment analysis (3). The scope of the selected studies 
ranged from comprehensive medical cost of radiotherapy including the depart-
ment’s overhead (20), to average cost specific to one pathology and/or treatment 
modality (25) to task-specific costs (7) e.g. shielding. Costs were computed per 
fraction and/or field (20), per treatment and/or patient (27) and specific to a treat-
ment’s process step (3). Costing methodologies ranged from detailed micro costing 
(13) to activity-based costing (5) to time-driven activity-based costing (2). Besides 
these established accounting methods, numerous “home-made” approaches were 
observed (23) and some studies didn’t state their method (7). cOnclusiOns: 
Due to heterogeneity both in methodology, input factors and paucity in costing 
method’s reporting, it was not possible to compare the cost estimates provided 
by these various studies. This comprehensive literature review of radiotherapy 
cost studies highlights the need for such studies to be conducted according to 
conventional accounting approaches and with rigor in the reporting of cost inputs 
and methodology.
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exTeNded-ReLease oxyCodoNe hydRoChLoRide (oxyCoNTiN®) foR 
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aNd PRivaTe heaLThCaRe sysTems PeRsPeCTives
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Objectives: The extended-release oxycodone hydrochloride is an opioid with 
similar action to morphine with proven efficacy in moderate to severe pain man-
agement. This study aims to develop a cost analysis of extended-release oxycodone 
versus morphine in an “if necessary” regime for cancer-related pain management, 
from the Brazilian public and private healthcare systems perspectives. MethOds: 
A decision model was developed to analyze the following strategies: group 1, 20 mg 
of extended-release oxycodone; group 2, 10 mg of extended-release oxycodone; 
and group 3, placebo. Efficacy data were obtained from Zhou e Wang, 2012. Direct 
costs were obtained from official price lists. Time horizon was determined through 
the hospital discharge period, and discount rates were not applied. Univariate sen-
sitivity analysis was performed to evaluate different hospital categories. Results: 
Total costs were 1,103 BRL, 1,071 BRL and 1,214 BRL per patient treated, from the 
public perspective, in groups 1, 2 and 3, respectively. The addition of oxycodone 
(10 and 20 mg) to the treatment reduced hospitalization stay, leading to savings 
of up to 143 BRL per patient, or a 12% reduction in total hospitalization cost. 
Total costs were 2,372 BRL, 2,367 BRL and 2,759 BRL per patient treated, from 
the private perspective, in groups 1, 2 and 3, respectively. The addition of oxyco-
done to treatment can lead to savings of up to 392.66 BRL per patient, a reduc-
tion about 14% of the total treatment cost during hospitalization. The univariate 
sensitivity analysis showed consistent results. cOnclusiOns: The inclusion of 
extended-release oxycodone can lead to a reduction in total costs related to pain 
treatment in patients with cancer, which would lead to resource savings for the 
payer.
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ToTaL aNNuaL CosT assoCiaTed WiTh BesT suPPoRTive CaRe of 
PaTieNTs WiTh uNReseCTaBLe advaNCed NoN-smaLL-CeLL LuNg 
CaNCeR uNdeR ReaL-WoRLd-CoNdiTioNs iN ReLaTioN To ResuLTs of 
iNTeRNaTioNaL sTudies
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GermanOncology GmbH, Hamburg, Germany
Objectives: Only a few international studies give valid information about cost 
of Best Supportive Care (BSC) of patients with unresectable advanced or meta-
static non-small-cell lung cancer (NSCLC). The aim of this non interventional 
study was to compare the results of these studies with data collected under 
real-world-conditions in 26 oncological practices in Germany. MethOds: Data 
collected from oncological practices in Germany contain information about the 
entire course of treatment including the medication of primary disease, radio-
therapy, number of outpatient specialist visits, length of hospitalisation, type 
and number of diagnostic and laboratory procedures. In addition, four different 
studies from USA, Scotland, Great Britain and the Netherlands with information 
about cost of BSC were examined. To compare these studies with data from the 
oncological practices, the results were transferred into the german reimbursement 
systems for health care services. The calculation for annual cost of treatment is 
based on methods of the Institute for Quality and Efficiency in Healthcare (IQWiG) 
in Germany. Results: 509 patients with NSCLC from 26 oncological practices 
throughout Germany were included in the statistical and cost´s analysis. Patients 
cal trial population were included in the estimation of total cost. HCRU costs were 
estimated using the mean reimbursed amounts from a cohort of breast cancer 
patients from the Truven Health Marketscan database. Study drug costs were esti-
mated using the unit wholesale acquisition cost for T-DM1 and L+C. Monthly costs 
were calculated by dividing the total cost by the observed survival time (in months). 
Total costs were evaluated using the Kaplan Meier Sample Average (KMSA) estima-
tor to account for differences in the length of follow-up and censoring between 
trial arms. Results: In the EMILIA clinical trial, median overall survival was 30.9 
months with T-DM1 (n= 495) versus 25.1 months with L+C (n= 496) after a median of 
19 months follow-up. No differences were observed in the monthly cost per-patient 
between T-DM1 ($7,151, 95% confidence interval [CI]: $6,753 - $7,550) and L+C ($7,909, 
95% CI: $5,095 - $10,723). The KMSA mean total costs were $331,083 (95% CI: $152,238 
- $506,128) and $264,421 (95% CI: $133,143- $412,927) in the T-DM1 and L+C arms, 
respectively. Hospitalization costs were lower among the T-DM1 arm ($9,634, 95% CI: 
$6,394 - $12,873) than the L+C arm ($11,286, 95% CI: $6,216 - $16,357). cOnclusiOns: 
Although the mean total costs were higher for T-DMI because of longer survival rela-
tive to L+C, the average monthly costs of treating patients with T-DM1 were similar 
to L+C. This study, along with the 5.8-month survival benefit, supports the potential 
value of T-DM1 for the treatment of HER2+ metastatic or locally advanced breast 
cancer.
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Objectives: To evaluate and compare surgical parameters and costs associated 
with robotic and laparoscopic surgery for colorectal cancer over 5-years (2009-2014) 
in a single Italian centre. MethOds: From 2009 to 2014 data about laparoscopic 
(LAP) and robotic (ROB) assisted colorectal cancer procedures performed in General 
Surgery, University Hospital of Pisa were collected. Operating time and length of 
stay were evaluated as surgical parameters and costs included fixed and variable 
items. Amortised cost of the robot and laparoscopic instrument and amortised 
cost of robot maintenance per intervention were considered among fixed costs. 
Variable costs included costs of dispensable equipment, cost of operating room 
personnel per time and costs of length-of-stay. Over the 5-years period surgical 
parameters and costs associated with LAP and ROB were analysed using descriptive 
statistics and compared between groups by independent T-test and Mann-Whitney 
test. Generalized linear models were used to assess the independent effect of type 
of surgery and time. Results: A total of 25 laparoscopic (LAP) and 50 robotic (ROB) 
procedures were evaluated. Overall median operating time was significantly higher 
in LAP (270 min vs 312.5 min, P= 0.006) and regression analysis showed a borderline 
significant interaction effect between type of surgery and years (P= 0.058) suggesting 
a significant reduction of operating time in ROB but not in LAP. Hospital-stay did 
not differ between groups (P= 0.567). Overall mean costs associated to LAP varied 
between 8,612±2,733 Euros in 2009 to 10,827±5,038 Euros in 2013. For ROB mean costs 
were 12,966±1,115 Euros in 2010 to 11,933±1,753 Euros in 2014. Regression analysis 
outlined significant greater costs for ROB (P-value< 0.001) without differences over 
time. cOnclusiOns: Robotic surgery for colorectal cancer carries out significant 
greater costs and operating time compared to laparoscopic surgery. There is weak 
evidence of improvement in the exploitation of ROB procedures without significant 
consequences on costs at present.
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CosTs To u.s. heaLTh iNsuReRs foR hemaToPoieTiC sTem CeLL 
TRaNsPLaNT (hCT) ReCiPieNTs WiTh douBLe sTRaNded dNa (dsdNa) 
viRus iNfeCTioNs foLLoWiNg TRaNsPLaNT
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Objectives: Patients undergoing HCT are at risk for infections, especially dsDNA 
viral infections (cytomegalovirus, BK Virus, Epstein-Barr Virus, HHV-6, herpes sim-
plex, herpes zoster, and adenovirus), for which there are limited viable preventative 
pharmacotherapies. Our objective was to compare direct medical costs reimbursed 
by health insurers following HCT for patients with dsDNA viral infection versus 
those without infections. MethOds: MarketScan Research Databases were used to 
identify patients with a first (index) procedure code for HCT between 01-July-2009 
and 30-June-2014. Eligible patients were required to have 365 days of health plan 
enrollment prior to HCT to understand baseline factors. Reimbursements were 
tabulated for up to 365 days post-transplant; univariate Wilcoxon tests compared 
reimbursements for patients with at least one dsDNA infection versus patients 
with no dsDNA infection. Results: The cohort included 6,553 HCT patients with 
no dsDNA viral infection (2,111 [32%] allogeneic, 4,442 [68%] autologous) and 1,275 
patients with at least one dsDNA viral infection (924 [72%] allogeneic, 351 [28%] 
autologous). Mean (SD; IQR) reimbursements for the 365 days post-transplant were 
$218,151 (SD= $209,717; IQR= $94,873-$276,992) for HCT recipients without dsDNA 
infections versus $470,784 (SD= $467,557; IQR= $193,854-$588,019; p= 0.0001) for 
those with any dsDNA viral infection. Among allogeneic HCT recipients, reim-
bursements were higher. Mean (SD; IQR) costs post-transplant for allogeneic HCT 
recipients without infection were $320,320 (SD= $278,388; IQR= $ 53,191-$405,450) 
versus $551,664 (SD= $503,913; IQR= $261,318-$654,483; p< 0.0001) for patients with 
any dsDNA viral infection and $999,010 (SD= $822,223; IQR= $449,033-$1,410,000) 
for patients with adenovirus infection. Adenovirus infection represented 4.5% 
of all dsDNA viral infections. cOnclusiOns: Patients who experience dsDNA 
viral infection following HCT have a higher burden of reimbursement com-
pared to those without such infections. dsDNA virus infections are most com-
mon and more costly in allogeneic HCT recipients. Measures to prevent dsDNA 
viral infection following HCT could result in cost savings and improved patient 
outcomes.
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presented in the guideline. A systematic review was performed on all the information 
about the dosage and frequency of administration found in the summary of product 
characteristics of the different products included in the treatment algorithms. Current 
pricing and reimbursement conditions in Spain of every biologic and chemotherapy 
drug considered in the guidelines were checked. Results: The first scenario, which 
places bevacizumab as first and second line treatment (concept of continuum of 
care) and anti-EGFR antibody as third line out of the four lines considered, yields an 
estimated OS of 20.2 months and total cost of 52,000€ per patient. The second scenario, 
which places bevacizumab as first line treatment and includes anti-EGFR antibody as 
second line in order to rescue the patients who have failed in the previous treatment, 
results in an estimated OS of 25.0 months and total cost of 50,000€ per patient. Finally, 
the third scenario places anti-EGFR antibody available for WT RAS patients as first 
line treatment and bevacizumab as second line out of three lines. When cetuximab is 
chosen as the anti-EGFR first line therapy, estimated OS is 33.1 months and the total 
cost does not exceed 40,000€ . cOnclusiOns: This analysis not only demonstrates 
that the use of more agents does not always assure a better clinical result, but that 
the use of cetuximab as first line treatment in WT RAS mCRC patients stands as the 
most efficient and cost-effective alternative maximizing OS.
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oRaL viNoReLBiNe PLus CisPLaTiN veRsus PemeTRexed PLus CisPLaTiN 
as fiRsT-LiNe TReaTmeNT foR PaTieNTs WiTh advaNCed NoN- squamous 
NoN- smaLL CeLL LuNg CaNCeR: a CosT miNimizaTioN aNaLysis iN 
TWeLve euRoPeaN CouNTRies
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1Pierre Fabre, Boulogne Billancourt, France, 2National Institute for Cancer Research, Genova, Italy
Objectives: Several platinum-based combination therapies can be used for the 
treatment of non-small lung cancer. According to a recent review, there is no clearly 
superior treatment in terms of effectiveness, the objective of our current study 
was to determine whether treatment with oral vinorelbine plus cisplatin can be 
potentially cost saving for payers, compared to treatment with pemetrexed and cis-
platin. MethOds: Considering the similar efficacy results of both treatment options 
in non-squamous non-small cell lung cancer patients (NS-NSCLC), as reported in a 
randomized phase II study (NAVoTRIAL01), a cost minimization analysis was con-
ducted across 12 European countries (Austria, Czech republic, Denmark, Finland, 
France, Germany, Greece, Norway, Slovak Republic, Spain, Switzerland, the UK). This 
analysis adopted the perspective of the National Health Service. Costs considered 
were those related to anticancer drugs, administration settings (i.e. out-patient/in-
patient/at home), serious adverse events and concomitant medications. All relevant 
costs were calculated based on country-specific reimbursement procedures and 
official tariffs. Results: Using the perspective of the National Health Service, the 
savings per patient treated with oral vinorelbine ranged from € 1,317 in Denmark 
to € 35,001 in Germany. Expressed as a percentage, it varies from 5% (France) to 
83% (Czech Republic). Pooled average costs for each treatment option across the 
12 countries resulted in an estimated cost saving of € 12,871 per patient favour-
ing treatment with oral vinorelbine plus cisplatin as opposed to treatment with 
pemetrexed plus cisplatin. Sensitivity analysis confirmed the robustness of the 
results. cOnclusiOns: This pan-European economic analysis provides economic 
evidence to support the use of oral vinorelbine instead of pemetrexed in the treat-
ment of NS-NSCLC. Indeed, oral vinorelbine provides similar efficacy and an eas-
ily manageable safety profile at a lower overall cost per patient treated (from the 
perspective of the NHS). These benefits are also supported by a convenient mode 
of administration for the patient.
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Objectives: The primary objective of this study is to identify the total cost of illness 
(COI) of metastatic NSCLC in the Netherlands during 2006-2012, from a healthcare 
perspective. Secondary objective is to identify whether changes in distribution of 
costs have occurred over the last years. MethOds: Patients diagnosed with met-
astatic NSCLC between 1-1-2006 and 31-12-2012, who had full follow-up and no 
registered trial participation were included. Patient charts were provided, and a 
structured chart review was performed using a case report form. Data collection 
started after diagnosis of metastatic NSCLC and ended at patient’s death. Data were 
collected of outpatient visits, clinical attendance, oncolytic drug use, imaging, lab 
tests, radiotherapy and surgery data. Results: In total 65 patients were included 
in this study. On average patients had 22.2 outpatient visits and 14.1 inpatient days. 
Diagnostic lab tests and imaging procedures were performed respectively 18.7 and 
13.0 times on average. Oncolytic drugs were used by 75% of patients; average 6.3 
intravenous administrations and 22.7 subscription days of oral oncolytic drugs. 
Total costs amounted to € 16,304, with oncolytic drugs (€ 6,625) and inpatient days 
(€ 5,104) as the main cost drivers. In comparison with the time-period of 2003-2005 
total treatment expenditures decreased by 53%. Of this total costs of treatment, the 
proportion of costs of oncolytic drugs increased from 16% to 41% and proportion of 
costs for outpatient visits decreased from 52% to 31%. cOnclusiOns: Outcomes 
in this study demonstrate that, compared to a recent study, the average cost for 
metastatic NSCLC has decreased over time in the Netherlands. A shift of main cost 
drivers seem to have taken place from inpatient stays in 2005, to costs of oncolytic 
drugs currently. This shift is possibly related to changes in patient management but 
also due to the increase of total expenditures on oncolytic drugs.
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The eCoNomiC BuRdeN of PRimaRy BRaiN TumoRs iN CaNada
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had to be in unresectable stage IIIB or stage IV and under current anticancer 
treatment at enrollment. The calculations included direct costs for radiotherapy, 
supportive and concomitant medication, involvement of other medical disciplines, 
hospitalisations, transfusions an other more. The total annual cost were in median 
10,098.00€ per patient. In contrast, the median annual cost of BSC in the four inter-
national studies were 29,621.48€ . cOnclusiOns: The results show a significant 
difference in the annual cost from data under real-world-conditions in relation to 
the median cost from the four international studies. A reason for the lower costs 
compared to the referenced studies could be the higher share of less expensive 
outpatient services in the german health system.
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a CosT ComPaRisoN of TReaTmeNT WiTh aBiRaTeRoNe aCeTaTe 
PLus PRedNisoNe iN The PRe ChemoTheRaPy seTTiNg foLLoWed By 
eNzaLuTamide iN The PosT-ChemoTheRaPy seTTiNg veRsus The 
oPPosiTe TReaTmeNT sequeNCe iN meTasTaTiC CasTRaTioN ResisTaNT 
PRosTaTe CaNCeR PaTieNTs WiTh NoN-visCeRaL meTasTases
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Objectives: Abiraterone acetate plus predniso(lo)ne (AA+P) and enzalutamide 
(ENZ) are novel anti-androgen therapies for the treatment of metastatic castration-
resistant prostate cancer (mCRPC) that are approved in both the pre-chemother-
apy and post-chemotherapy settings. The aim of this study is to estimate and 
compare the costs associated with two treatment sequences: AA+P followed by 
docetaxel (DOC) chemotherapy and then ENZ (‘AA+P-DOC-ENZ sequence’) versus 
ENZ followed by DOC chemotherapy and then AA+P (‘ENZ-DOC-AA+P sequence’) 
in mCRPC patients with non-visceral metastases. MethOds: A health economic 
model has been developed to estimate and compare the cost consequences of 
these two treatment sequences in the UK. Seven health states were considered in 
the model: pre chemotherapy treatment (AA+P or ENZ), active monitoring (before 
and after chemotherapy separately), DOC chemotherapy, post-chemotherapy 
treatment (AA+P or ENZ), best supportive care, and death. Clinical input data 
(e.g., duration of treatment, time to chemotherapy) for the model were derived 
from published pivotal trial results. Costs parameters were derived from avail-
able literature and the manufacturers’ published reimbursement submission 
dossiers. List prices of drugs were used. For each treatment sequence, the model 
estimated total costs and total costs per health state. Results: The total costs 
were estimated to be £75,956 for the ‘AA+P-DOC-ENZ sequence’ and £80,591 for 
the ‘ENZ-DOC-AA+P sequence’ resulting in a total cost difference of £4,636. Pre-
chemotherapy costs of AA+P and ENZ treatment were estimated to be £43,817 
and £48,860, respectively (difference £5,043). With respect to the other health 
states, similar costs were estimated for the two sequences, e.g., post-chemother-
apy costs of AA+P and ENZ treatment were predicted to be £9,481 and £8,974, 
respectively. cOnclusiOns: The results of the health economic model suggest 
that the ‘AA+P-DOC-ENZ sequence’ yields lower total costs than the ‘ENZ – DOC- 
AA+P sequence’ and therefore starting treatment with AA+P may result in cost 
savings.
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a CosT-effeCTiveNess aNaLysis of gefiTiNiB as The fiRsT LiNe 
TReaTmeNT iN PaTieNTs WiTh PosiTive egfR muTaTioN iN meTasTaTiC oR 
LoCaLLy advaNCed NoN-smaLL CeLL
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Objectives: Assess the cost-effectiveness of tyrosine kinase inhibitors (TKIs) on an 
EGFR+ NSCLC population under the Brazilian private healthcare system. MethOds: 
A cost-effectiveness analysis (CEA), based on a Markov framework with monthly 
cycles, was performed to evaluate costs and effects of gefitinib versus erlotinib 
on an EGFR+ NSCLC population over a 1 year period. Outcomes measured were 
overall survival (OS), progression free survival (PFS), Quality Adjusted Life Years 
(QALYs) and total costs. Direct medical costs were assessed, including treatment 
and genome testing costs. Treatment costs were based on ex-factory prices and 
label defined posologies. Efficacy data was based on a meta-analysis by Gao et 
al. Results: Gefitinib was equivalent to erlotinib regarding effectiveness outcomes, 
showing incremental results of 0, -0.02 and -0.01 for OS, PFS and QALY over a 1 year 
time horizon, respectively. Costs were significantly lower on patients treated with 
gefitinib than on those treated with erlotinib. On a scenario where genome test-
ing was not performed gefitinib showed a total cost of R$ 21,580.56 (US$ 6,916.67) 
while erlotinib showed total costs of R$ 39,393.24 (US$ 12,626.04), resulting in an 
incremental cost of -R$ 17,812.98 (-US$ 5,709.29). Genome testing added R$ 1,000.00 
(US$ 320.51) to both arms, resulting in R$ 22,580.56 (US$ 7,237.36) and R$ 40,393.24 
(US$ 12,946.55). cOnclusiOns: Regarding effectiveness, both TKIs showed a similar 
profile. Those results are confirmed by a recent meta-analysis by Haaland et al. 
Therefore, in this economic model gefitinib and erlotinib showed similar efficacy 
profile with gefitinib representing a less costly treatment choice than erlotinib for 
the Brazilian private healthcare system.
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aNaLysis of CLiNiCaL aNd eCoNomiC imPLiCaTioNs of esmo 2014 
CLiNiCaL PRaCTiCe guideLiNes foR meTasTaTiC CoLoReCTaL CaNCeR 
TReaTmeNT
Suarez J
Merck, Madrid, Spain
Objectives: ESMO Clinical Guidelines for metastatic Colorectal Cancer treatment 
(mCRC) were updated in 2014. The objective is to assess the clinical (measured by 
overall survival, OS) and economic implications of its recommendations from the 
Spanish national healthcare system view. MethOds: A calculator was designed in 
order to analyze and compare the clinical and economic outcomes of the scenarios 
